News

Velocity Joins Advarra’s Council for Responsible Use of AI in Clinical Trials as Founding Member

We’re proud to share that Velocity Clinical Research has joined Advarra’s newly launched Council for Responsible Use of AI in Clinical Trials as a founding member—alongside fellow industry leaders from Sanofi and Recursion. This cross-industry initiative will focus on setting standards, defining measurable outcomes, and guiding the ethical use of AI across the clinical trial … Read more

BioSpace Article: U.S. Uncertainty Creates Clinical Trial Leadership Opportunity for Europe

The U.S. clinical research landscape faces uncertainty. NIH grant cancellations, FDA staffing cuts, and regulatory uncertainty are creating real challenges for the industry’s traditional leader. Europe has an opportunity if it acts decisively. In his latest op-ed for BioSpace, Craig Koch examines why this moment matters for European clinical research. While the EEA’s share of … Read more

Velocity’s VISION Reaches More than $12.6 Million in Payments and 10,000 Randomizations

VISION has now contributed to more than 10,000 participant randomizations worldwide. Additionally, over $12.6 million in stipends have been paid through the VISION Engage mobile app, which is active in four countries and available in four languages. VISION continues to connect more people to clinical trials, enhance the participant experience, and reduce site burden. Learn … Read more

Henrik Watz, MD, PhD, Named Top COPD Scholar

Henrik Watz, MD, PhD, has been named a 2024 Top Scholar by ScholarGPS, ranked #34 globally among chronic obstructive pulmonary disease (COPD) researchers over the past five years, and recognized among the top 0.5% of all researchers worldwide. Over the past year, Dr. Watz has: Presented compelling real-world data at ATS 2025 on the long-term … Read more

Henrik Watz, MD, PhD, Presents Promising Asthma Trial Results at ATS 2025

Henrik Watz, MD, PhD, presented compelling real-world data at the American Thoracic Society Annual Meeting on the long-term impact of dupilumab therapy in patients with severe asthma. Participants in the ProVENT study experienced sustained improvements in lung function, asthma control, and quality of life. Notably, more than half achieved asthma remission within two years of … Read more

Velocity Sites Help Deliver Promising Results in NEJM: Once-Weekly Semaglutide Shows Positive Affect on MASH, Liver Fibrosis

Velocity’s sites in Dallas, TX, and Staszów, Poland, enrolled patients in Novo Nordisk’s Phase 3 trial assessing semaglutide’s effect on participants with metabolic dysfunction–associated steatohepatitis (MASH). Trial results were published in a recent New England Journal of Medicine article detailing the GLP-1 receptor agonist’s impact on liver fibrosis. The study found that “in patients with … Read more

Brandon Essink, MD, CPI, Publishes Article for ACRP and Clinical Trials Day

In this article, Brandon Essink, MD, CPI, examines a critical challenge in clinical research: Principal Investigator attrition. Why do so many PIs leave research after just one trial? How can we support a sustainable, talented pipeline of investigators? What practical steps can Sponsors, CROs, and sites take to empower physicians to enter, stay, and thrive … Read more

Paul Evans Featured in Applied Clinical Trials Article on Impact of Executive Orders on DEI Initiatives

Paul Evans was featured in Applied Clinical Trials‘ latest article weighing in on the real-world implications of recent executive orders affecting DEI initiatives nationwide. In the piece, Paul underscores Velocity’s unwavering commitment to inclusive, patient-centered research environments, stating: “Velocity believes that clinical trials should be a safe space for the entire LGBT community… It’s important … Read more